SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Asia Conference in Kuala Lumpur, Malaysia.
NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Asia Conference in Kuala Lumpur, Malaysia.
Dr. Gomez will present on “Medical Preparedness for Chemical, Biological, Radiological and Nuclear Defense (CBRNe) Events” at 4:00 p.m. Malaysia Time on Wednesday, October 23, 2019. He will be speaking at the conference in support of SIGA’s collaboration with Meridian Medical Technologies, Inc. (a Pfizer Company), with which SIGA announced an international promotion agreement for TPOXX (tecovirimat) oral capsules in June 2019.
“We are pleased to have this opportunity to share information about TPOXX and the role it might play in effectively preparing for and responding to a smallpox outbreak with Asian organizations focused on biopreparedness,” said Dr. Gomez.
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and intravenous (IV) formulation antiviral medicine for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of 1.7 million courses in the Strategic National Stockpile under Project BioShield. The FDA approved the oral formulation of TPOXX for the treatment of smallpox in July 2018. In September 2018, SIGA signed a new contract with Biomedical Advanced Research and Development Authority (BARDA) for procurement of oral and intravenous formulations of TPOXX, and development activities. For more information about SIGA, please visit www.siga.com.
About Smallpox1
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
Contacts:
Investors
David Carey
212-867-1768
[email protected]
Media
Stephanie Seiler
206-713-0124
[email protected]
1http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
